A new study provides more evidence that women who are at increased risk of developing breast cancer can significantly reduce their risk by having both breasts removed, a procedure known as bilateral prophylactic mastectomy. The risk reduction in the current study was about 95 percent.
The Food and Drug Administration (FDA) approved Symlin, an injectable medicine to control blood sugar for adults with type 1 and type 2 diabetes. Symlin is to be used in addition to insulin therapy in patients who cannot achieve adequate control of their blood sugars on intensive insulin therapy alone.
The Food and Drug Administration (FDA) has granted approval of a new indication for Temodar (temozolomide). The drug, used concurrently with radiotherapy and as maintenance therapy after radiotherapy, can extend the lives of adult patients newly diagnosed with glioblastoma multiforme (GBM), the most common form of malignant brain cancer.
Adding etidronate to calcium and vitamin D therapy is not necessary in the treatment of bone loss in patients with Crohn’s disease, results of a new study indicate. “The addition of the bone-building drug etidronate adds no additional advantage,” Dr. Richard N. Fedorak told.
The Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (nataluzimab) while the agency and the manufacturer evaluate two serious adverse events reported with its use.
Bipolar disorder may often go undiagnosed and untreated in the urban poor, with 1 in 10 found to have the mental illness in a study of one New York clinic published on Tuesday 2005-02-22.
Pre-diabetes – the term, recently coined by health officials, indicates a partly elevated blood sugar level that will likely develop into full diabetes within 10 years if nothing is done to stop it.
Individuals living with HIV and AIDS may not only have to deal with the threat of illness but the toll of illness. All that is required to stay healthy and alive can leave an everlasting mark! I’m referring to the loss of subcutaneous fat from the face, commonly referred to as facial wasting or Lipoatrophy.
Genzyme Corp. announced that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).
The Food and Drug Administration (FDA) approved a new intravenous biologic product, palifermin (trade-name Kepivance) to help reduce the chance that certain cancer patients, those with blood cancers undergoing chemotherapy and radiation in preparation for bone marrow transplants, will develop mucositis. Palifermin also shortens the duration of the condition.